A Phase 1, Single Center, Open-label, Single Period, Non-randomized Study to Determine the Absolute Bioavailability of Bexagliflozin Tablets Following a Single Oral Dose Co-administered With an Intravenous Microtracer Dose of 14C-Bexagliflozin in Healthy Male Subjects
Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 03 Jul 2018
At a glance
- Drugs Bexagliflozin (Primary) ; Bexagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Theracos
- 20 Jun 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 26 Apr 2018 Planned End Date changed from 16 May 2018 to 16 Sep 2018.
- 26 Apr 2018 Planned primary completion date changed from 16 May 2018 to 16 Sep 2018.